Global Marine Energy Market Analysis to 2020 - Capacity, Generation, Regulation and Market Share Analysis Vijaya 11.5606
In 2009, the global men ’ s health market was estimated to be worth $4,019m, representing a cumulative annual growth rate (CAGR) of 7.9% between 2001 and 2009. By 2016, the global men ’ s health market is estimated to reach $5,509m, indicating a CAGR of 4.6% between 2009 and 2016. The major reason for the reduced growth rate is the patent expiry of a blockbuster drug. The global men ’ s health market is expected to witness patent expiry of a major blockbuster drug, Viagra. The drug contributes significantly in total men ’ s health market. Hence, patent expiry of the drug will directly affect the market growth.
For more information or to buy this report please click here add this link to your browser:
The men ’ s health pipeline portfolio has 43 projects across different developmental stages. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 69% of the total number of pipeline programs. In addition, the pipeline of two major markets, erectile dysfunction and male hypogonadism are holding 81% of the total pipeline molecules. This indicates that the launch of these drugs will boost the ED and male hypogonadism market. ED pipeline has five molecules in Phase III. Among these, avanafil, udenafil and TA-1790 are me- too molecules. These drugs are phosphodiesterase type 5 inhibitors and expected to be launched in the near future. Other, Phase III candidates such as Alfuzosin and Vitaros are first-in-class molecules. Launch of these molecules will again support the market growth. The male hypogonadism pipeline has three molecules in each regulatory filing and Phase III stages. The premature ejaculation market also has three molecules in Phase III. The fact that PE market does not have any FDA approved molecules, introduction of new drugs will boost the market significantly.
GBI Research, the leading business intelligence provider, has released its latest research, “ The Men's Health Therapeutics Market to 2016 – Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors will Dominate the Market ” . It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global men ’ s health market. The report analyzes the markets for men ’ s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
For more information or to buy this report please click here add this link to your browser:
Visit our report store: http://www.gbiresearch.com
For more details contact:
info@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
Add this page to your favorite Social Bookmarking websites
